Being an exceptional compounding professional means you never stop learning
Few areas of compounding policy are evolving faster than that regarding certain peptides that don’t currently meet the statutory requirements for use in human drugs. Flourishing illicit markets for these substances are putting patients at risk and represent a public health threat. The Alliance for Pharmacy Compounding supports a well-defined pathway that moves patients and ingredients out of those illicit markets and into the regulated healthcare system.
In July 2026, FDA’s Pharmacy Compounding Advisory Committee narrowly recommended that six peptides, none of them FDA-approved drugs, be eligible for compounding. APC has asked FDA to concur and, rather than rush to final rulemaking, permit compounding of these six peptides through enforcement discretion, subject to defined safeguards.
APC is not advocating unrestricted peptide compounding. The goal is a pathway that patients, providers, regulators and the public can trust.
Where APC stands
Patients seeking peptides are better served within the regulated healthcare system than outside it. For the six peptides PCAC recommended in July 2026, APC has urged FDA, policymakers and the committee itself to support a pathway built on these safeguards.
API bought only through an FDA-registered repackager, relabeler or reseller that has validated the manufacturer and its Certificate of Analysis, with lot-specific documentation of provenance.
Every preparation under the proposed pathway would originate with a prescriber’s clinical judgment and prescriber-patient relationship.
A standardized notice that the preparation is compounded and not FDA-approved, and that evidence on the active ingredient may be limited.
Serious adverse events reported through FDA’s MedWatch program, with records that support investigations and recalls.
FDA keeps acting against sellers marketing illicit “research use only” products for human use.
Putting safety reports in context
Under APC’s proposal, pharmacies compounding the six peptides would report a small set of de-identified dispensing data (the peptide, dosage form and strength, patient gender where available, and month of fill) through OPEN, a research initiative led by an independent academic partner. Only aggregate results would be shared, giving FDA the context it needs to interpret safety reports.
USP standards, state pharmacy laws and board-of-pharmacy oversight would continue to apply. The pathway adds safeguards; it does not replace existing requirements.
Read APC’s position in full
Download the issue brief, letter and memo for the full details behind APC’s position.
APC in the news
Reporters covering peptides have turned to APC for the compounding perspective.
FDA peptide review could lead to new compounding boom
CNN July 22, 2026The future of peptides in the US is about to become clearer. Here’s what you should know
Politico June 30, 2026FDA unveils peptides position
Men’s Health April 23, 2026Wait, So Are Peptides Legal Now?
Washington Post April 15, 2026Amid wellness craze, FDA weighs lifting peptide restrictions
NPR March 31, 2026The wellness world is eager for RFK Jr.’s promised move on peptides
Peptides will remain one of the most closely watched areas of compounding. That attention is healthy, and APC is ready for it. Serious conversations about quality, sourcing, transparency and stewardship are how a legitimate pathway earns the confidence of patients, providers, regulators and the public.
Defending access alone isn’t enough. APC will keep engaging these questions thoughtfully, advocating for patient safety and working to ensure compounding remains a credible, responsible part of patient care.
.png?width=17&height=16&name=folder%20(1).png){kind=small}
